Citations

Clear

415 citation(s) found for "Black, DF".

Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer
Sartor, Oliver , Sartor, A Oliver , Jang, Albert , Ledet, Elisa M.

Mayo Clinic

The Oncologist | August 11, 2023 | Volume: 28 | Issue: 11 | Pages: e1127-e1128

10.1093/oncolo/oyad240 | PMID 37589230 Get It

Considering recently published data, this letter to the editor highlights the clinical relevance of CDK12 pathogenic or likely pathogenic mutations, noting that Black men have prostate cancers with increased rates of this pathologic alteration. Practitioners should be made aware of recent findings, given that CDK12 mutations are known to be associated with aggressive variants of prostate cancer and that they may confer susceptibility to PD-1 antagonists.
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss, Aaron R. , Scharschmidt, Thomas J. , Xue, Wei , Gao, Zhengya, Black, Jennifer O. , Choy, Edwin , Fanburg–Smith, Julie C. , Kao, Simon C. , Kayton, Mark L. , Kessel, Sandy, Lim, Ruth , Million, Lynn , Okuno, Scott H. , Ostrenga, Andrew , Parisi, Marguerite T. , Pryma, Daniel A. , Rosen, Mark, Terezakis, Stephanie , Venkatramani, Rajkumar , Zambrano, Eduardo , Wang, Dian , Hawkins, Douglas S. , Black, Jennifer O , Choy, Edwin , Kao, Simon C , Kayton, Mark L , Lim, Ruth , Million, Lynn , Okuno, Scott , Ostrenga, Andrew , Pryma, Daniel A , Randall, Robert Lor , Shulkin, Barry L , Terezakis, Stephanie A , Venkatramani, Rajkumar , Wang, Dian , Hawkins, Douglas S , Spunt, Sheri L , Weiss, Aaron R , Chen, Yen‐Lin , Davis, Jessica L. , Randall, R. Lor , Shulkin, Barry L. , Spunt, Sheri L.

Mayo Clinic

Journal of Clinical Oncology | July 31, 2023 | Volume: 41 | Issue: 31 | Pages: 4842-4848

10.1200/jco.23.00045 | PMID 37523624 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867 ). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B ( P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B ( P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.
Creating an appetite awareness and lifestyle modification intervention for Black women at risk for binge eating disorder: A pilot open trial
Goode, Rachel W. , Bardone‐Cone, Anna M. , Wilhoit-Reeves, Stephanie B., Williams, Lesley, Malian, Hannah M., Coan, Danielle, Noem, Taylor, Tate, Deborah F. , Tate, Deborah F

Mayo Clinic

Clinical Obesity | July 28, 2023 | Volume: 13 | Issue: 6 | Pages: No page available

10.1111/cob.12613 | PMID 37501401 Get It

SummaryDespite the availability of evidence‐based interventions to improve binge eating, Black women have some of the lowest rates of access to care for eating disorders. Innovation is needed to offer accessible and culturally relevant treatment options. To this end, using an open trial design, we investigated the feasibility and acceptability of a group‐based, appetite awareness training (AAT) + lifestyle modification (LM) programme in Black women at risk for BED in a primary care setting. Participants (n = 20) were Black women recruited from a family medicine centre affiliated with a local public university, and who reported at least two binge eating episodes in the last 28 days. Participants completed a 16‐session AAT + LM programme over 4 months. Key outcomes were objective binge eating (assessed by the EDE and the EDE‐Q), body dissatisfaction, and weight change, all assessed at baseline, four (post‐treatment) and 6 months (2‐month follow‐up). Ninety‐five percent of participants completed assessments at post‐treatment and attended nearly 60% of intervention sessions. Among completers (n = 19), body dissatisfaction and objective binge eating decreased from baseline to post‐treatment and this decrease was maintained at the 2‐month follow‐up. In exit interviews, participants reported programme satisfaction. Providing training in appetite awareness combined with lifestyle modification principles may be useful in the treatment of body dissatisfaction and binge eating among Black women.
Hearing, β-Amyloid Deposition and Cognitive Test Performance in Black and White Older Adults: The ARIC-PET Study
Deal, Jennifer A. , Jiang, Kening , Sharrett, A. Richey , Reed, Nicholas S. , Knopman, David S. , Wong, Dean F. , Lin, Frank R. , Knopman, David S. , Deal, Jennifer A , Rawlings, Andreea M. , Mosley, Thomas H. , Zhou, Yun , Gottesman, Rebecca F.

Mayo Clinic

The Journals of Gerontology: Series A | July 7, 2023 | Volume: 78 | Issue: 11 | Pages: 2105-2110

10.1093/gerona/glad159 | PMID 37419460 Get It

Abstract Background Hearing loss is a risk factor for dementia; whether the association is causal or due to a shared pathology is unknown. We estimated the association of brain β-amyloid with hearing, hypothesizing no association. As a positive control, we quantified the association of hearing loss with neurocognitive test performance. Methods Cross-sectional analysis of Atherosclerosis Risk in Communities-Positron Emission Tomography study data. Amyloid was measured using global cortical and temporal lobe standardized uptake value ratios (SUVRs) calculated from florbetapir-positron emission tomography scans. Composite global and domain-specific cognitive scores were created from 10 neurocognitive tests. Hearing was measured using an average of better-ear air conduction thresholds (0.5–4 kHz). Multivariable-adjusted linear regression estimated mean differences in hearing by amyloid and mean differences in cognitive scores by hearing, stratified by race. Results In 252 dementia-free adults (72–92 years, 37% Black race, and 61% female participants), cortical or temporal lobe SUVR was not associated with hearing (models adjusted for age, sex, education, and APOE ε4). Each 10 dB HL increase in hearing loss was associated with a 0.134 standard deviation lower mean global cognitive factor score (95% CI: −0.248, −0.019), after adjustment for demographic and cardiovascular factors. Observed hearing-cognition associations were stronger in Black versus White participants. Conclusions Amyloid is not associated with hearing, suggesting that pathways linking hearing and cognition are independent of this pathognomonic Alzheimer’s-related brain change. This is the first study to show that the impact of hearing loss on cognition may be stronger in Black versus White adults.
Facial Morphometrics in Black Celebrities: Contemporary Facial Analysis Using an Artificial Intelligence Platform
Salinas, Cristina A., Liu, Alice , Sharaf, Basel , Sharaf, Basel A, Sharaf, Basel A

Mayo Clinic

Journal of Clinical Medicine | July 6, 2023 | Volume: 12 | Issue: 13 | Pages: 4499

10.3390/jcm12134499 | PMID 37445534 Get It

The diversity of patients pursuing facial aesthetic and facial gender-affirming surgery (FGAS) is increasing, yet there is a paucity of objective guidelines to facilitate surgical decision-making in patients of color. We conducted a quantitative analysis of black celebrities using standardized frontal photos of 21 female and 21 male celebrities. Celebrities were chosen from popular entertainment magazines and websites, including People Magazine, the Internet Movie Database (IMDb), Cosmopolitan, and Essence. For each celebrity, 100 facial landmarks were detected through a facial analysis artificial intelligence (AI) program. Black males had greater facial height, bizygomatic width, lower facial height, and bigonial width than females. However, the facial height to bigonial width ratio was similar between genders and approximated the golden ratio (1.618). Female faces demonstrated a greater mid-face height to total facial height proportion, and males had a greater lower facial height proportion. Females exhibited an upward-slanted medial brow and shorter total eyebrow length, nose height, and alar width. Forehead height above the lateral brow was greater in males, while central forehead height was similar to females. This is the first study that has utilized AI to provide ethnicity-specific facial morphometrics relevant to facial rejuvenation and FGAS in the black population.
Abstract 1213: Impact of pesticide exposure in West African Black men within the United States, Cameroon, and Nigeria
Asto-Flores, Emelina , Ademola, Popoola, Jibrin, Paul, Sowumi, Anthonia, Nkegoum, Blaise , Oladoyinbo, Catherine, Salako, Abdulkadir Ayo, Omonisi, Abidemi , Bassey, Iya Eze , Adeniji, Kayode , Asura, Nggada Haruna, Kukoyi, Oluwole, Enuka, Ruth, Toye, Oluwaseyi, Crook, Jennifer , Investigators, CaPTC, Iweala, Emeka Eze Joshua , Faruk, Mohammed , Fatiregun, Omolara , Okoye, Ifeoma Joy , Kaninjing, Ernest , Fathi, Parisa , Enuka, Ruth, Toye, Oluwaseyi

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 1213-1213

10.1158/1538-7445.am2023-1213 Get It

Abstract Prostate cancer (CaP) significantly affects black men causing highermortality rates especially within African and Caribbean countries. The Prostate Cancer Transatlantic Consortium (CaPTC) is a 10 year longitudinal study aimed at studying environmental, epidemiological and prostate cancer associated risk factors within black men of West African descent living in the United States (US), Cameroon, and Nigeria. Methods: Men ages 35- 70 years old, who identified as a US Black male or West African Black male immigrant in the US, were recruited from community-based organizations. Community- based organizations include local churches, health fairs and socialorganizations. Anthropometric, environmental, and epidemiological variables measures were collected via survey questions. Saliva samples were collected using Salimetrics. Mean and range from the survey questions were categorized and a logistical regression model was used to determine associations between variables. Results: Logistical analysis output for analysis of pesticide exposure and cancer diagnosis within the three countries, found participants in Nigeria who were exposed to pesticide use, to be a significant predictor of cancer diagnosis (p 0.013). The age of exposure was another variable analyzed to see whether there was a correlation between age of exposure in pesticide use and cancer diagnosis. No significant predictors were determined yet a reasoning to why a significance is not yet found could be due to many participants needing a closer examination into the consequences of early exposure to known carcinogens. Conclusion: Significant data was found between pesticide exposure and cancer diagnosis between the US, Cameroon, and Nigeria in West African Black men. Regarding age of pesticide exposure and the relation between cancer diagnosis, more data needs to be collected regarding these variables. Significance in determining pesticide use as a predictor for cancer diagnosis in black males, can lead to increased efforts in pesticide exposure education in addition to possible government reformation on laws regarding pesticide use. Citation Format: Emelina Asto-Flores, Iweala Emeka, Popoola Ademola, Paul Jibrin, Mohammed Faruk, Anthonia Sowumi, Omolara Fatiregun, Nkegoum Blaise, Catherine Oladoyinbo, Ifeoma Okoye, Abdulkadir Ayo Salako, Abidemi Omonisi, Iya Eze Bassey, Kayode Adeniji, Nggada Haruna Asura, Ernest Kaninjing, Oluwole Kukoyi, Parisa Fathi, Ruth Enuka, Oluwaseyi Toye, Jennifer Crook, CaPTC Investigators, Folakemi Odedina. Impact of pesticide exposure in West African Black men within the United States, Cameroon, and Nigeria [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1213.
Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study
Ben‐Joseph, Rami , Saad, Ragy , Black, Jed , Dabrowski, Elizabeth , Gallucci, Sophia, Taylor, Ben , Somers, Virend K.

Mayo Clinic

SLEEP | June 8, 2023 | Volume: 46 | Issue: 10 | Pages: No page available

10.1093/sleep/zsad161 | PMID 37305967 Get It

Abstract Study Objectives Narcolepsy is associated with cardiovascular risk factors; however, the risk of new-onset cardiovascular events in this population is unknown. This real-world study evaluated the excess risk of new-onset cardiovascular events in U.S. adults with narcolepsy. Methods A retrospective cohort study using IBM MarketScan administrative claims data (2014–2019) was conducted. A narcolepsy cohort, comprising adults (≥18 years) with at least two outpatient claims containing a narcolepsy diagnosis, of which at least one was non-diagnostic, was matched to a non-narcolepsy control cohort (1:3) based on cohort entry date, age, sex, geographic region, and insurance type. The relative risk of new-onset cardiovascular events was estimated using a multivariable Cox proportional hazards model to compute adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results The narcolepsy and matched non-narcolepsy control cohorts included 12 816 and 38 441 individuals, respectively. At baseline, cohort demographics were generally similar; however, patients with narcolepsy had more comorbidities. In adjusted analyses, the risk of new-onset cardiovascular events was higher in the narcolepsy cohort compared with the control cohort: any stroke (HR [95% CI], 1.71 [1.24, 2.34]); heart failure (1.35 [1.03, 1.76]); ischemic stroke (1.67 [1.19, 2.34]); major adverse cardiac event (1.45 [1.20, 1.74]); grouped instances of stroke, atrial fibrillation, or edema (1.48 [1.25, 1.74]); and cardiovascular disease (1.30 [1.08, 1.56]). Conclusion Individuals with narcolepsy are at increased risk of new-onset cardiovascular events compared with individuals without narcolepsy. Physicians should consider cardiovascular risk in patients with narcolepsy when weighing treatment options.
Abstract IA007: Science of prostate cancer care and survivorship in black men: Structural, social and biological determinants
Odedina, Folakemi T., Dronca, Roxana , Ashing, Kimlin , Kaninjing, Ernest , Rotimi, Solomon O. , Ngufor, Che

Mayo Clinic

Cancer Research | June 2, 2023 | Volume: 83 | Issue: 11_Supplement | Pages: IA007-IA007

10.1158/1538-7445.prca2023-ia007 Get It

Abstract Black men are disproportionately affected by prostate cancer (CaP), with limited progress in closing the CaP care and survivorship gaps experienced by Black men compared to other racial/ethnic groups. Unfortunately, there is an uptick in CaP incidence rate in the United States (US) since 2014. As reported by the American Cancer Society, the rising CaP incidence rate indicates a shift towards higher grade and stage during diagnosis. The prostate cancer (CaP) disparities experienced by Black men in the US is a microcosm of the global burden of CaP seen in men of African ancestry. For example, the top ten countries leading CaP mortality in the world are all Black nations in Africa and the Caribbean. The complexity of CaP disparities and the need for a unique approach to better understand and address a complex chronic disease, such as CaP, underscores the need for consortium research that is multilevel, collaborative, translational, and global. Through the Department of Defense funding, we formed an inclusive Cancer Care Research Equity (iCCaRE) for Black Men Consortium to advance health equity and reduce disparities in CaP. Comprising CaP survivors, advocates, scientists, and clinicians, the iCCaRE for Black Men Consortium addresses structural, social and biological determinants of CaP among ethnically diverse Black men globally, including US Black men, West African immigrant men in the US and indigenous West African men. The overall goal of the iCCaRE consortium is to optimize CaP diagnosis experiences, treatment and survivorship based on the Science of Survivorship (SOS). Our central hypothesis is that improving social-determinants of health (SDOH) factors, CaP care and survivorship (CaPCaS)-related factors and mediating biological factors will lead to an improvement in patient-reported outcomes (PROs). This presentation will highlight the structural inequities, societal injustices and biological determinants found to be associated with CaP care and survivorship among Black men. Additionally, we will present the use of Community Living Lab (CoLLab) Health System approach to address inequity in minoritized and marginalized communities. Citation Format: Folakemi Odedina, Roxana Dronca, Kimlin Ashing, Ernest Kaninjing, Solomon Rotimi, Che Ngufor, Arnold Merriweather, iCCaRE Consortium. Science of prostate cancer care and survivorship in black men: Structural, social and biological determinants [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr IA007.
Experience with the US health care system for Black and White patients with advanced prostate cancer
Rencsok, Emily M. , Ragin, Camille, Nowak, Joel , McSwain, Lawrence, Manarite, Jan, Heath, Elisabeth I. , George, Daniel J. , Vinson, Jacob, Villanti, Paul , Haneuse, Sebastien , Mucci, Lorelei A. , Registry, the IRONMAN, George, Daniel J , Haneuse, Sebastien , Stopsack, Konrad H. , Slopen, Natalie , Ragin, Camille , Kantoff, Philip W. , Registry, the IRONMAN

Mayo Clinic

Cancer | May 29, 2023 | Volume: 129 | Issue: 16 | Pages: 2532-2541

10.1002/cncr.34885 | PMID 37246339 Get It

AbstractObjectiveThe purpose of this study was to assess differences in reported information about treatment, integration into care, and respect by self‐identified Black and White individuals with advanced prostate cancer in the United States.Patients and MethodsThis is a prospective cohort study of 701 participants (20% identifying as Black) enrolled in the International Registry for Men with Advanced Prostate Cancer at 37 US sites from 2017 to 2022. Participants were asked six questions from the Cancer Australia National Cancer Control Indicators about their experience with care at study enrollment. Prevalence differences by self‐reported race were estimated using marginal standardization of logistic‐normal mixed effects models (adjusted for age at enrollment and disease state at enrollment), and 95% CIs were estimated using parametric bootstrapping.ResultsMost participants reported a high quality of care for each question. Black participants generally reported higher care quality compared with White participants. Black participants reported more frequently that they were offered a written assessment and care plan (71%) compared with White participants (58%; adjusted difference, 13 percentage points; 95% CI, 4–23). Black participants also reported more frequently being given the name of nonphysician personnel who would support them (64%) than White participants (52%; adjusted difference, 10; 95% CI, 1–20). Prevalence differences did not differ by disease state at enrollment.ConclusionsBlack participants generally reported a higher quality of care compared with White participants. This study calls attention to the need to study potential mediating factors and interpersonal aspects of care in this population to improve survivorship.
Determination of the Duplicated CYP2D6 Allele Using Real-Time PCR Signal: An Alternative Approach
Atiq, Mazen A. , Peterson, Sandra E. , Langman, Loralie J., Baudhuin, Linnea M. , Black, John L. , Moyer, Ann M. , Moyer, AM , Atiq, Mazen

Mayo Clinic

Journal of Personalized Medicine | May 25, 2023 | Volume: 13 | Issue: 6 | Pages: 883

10.3390/jpm13060883 | PMID 37373874 Get It

CYP2D6 duplication has important pharmacogenomic implications. Reflex testing with long-range PCR (LR-PCR) can resolve the genotype when a duplication and alleles with differing activity scores are detected. We evaluated whether visual inspection of plots from real-time-PCR-based targeted genotyping with copy number variation (CNV) detection could reliably determine the duplicated CYP2D6 allele. Six reviewers evaluated QuantStudio OpenArray CYP2D6 genotyping results and the TaqMan Genotyper plots for seventy-three well-characterized cases with three copies of CYP2D6 and two different alleles. Reviewers blinded to the final genotype visually assessed the plots to determine the duplicated allele or opt for reflex sequencing. Reviewers achieved 100% accuracy for cases with three CYP2D6 copies that they opted to report. Reviewers did not request reflex sequencing in 49–67 (67–92%) cases (and correctly identified the duplicated allele in each case); all remaining cases (6–24) were marked by at least one reviewer for reflex sequencing. In most cases with three copies of CYP2D6, the duplicated allele can be determined using a combination of targeted genotyping using real-time PCR with CNV detection without need for reflex sequencing. In ambiguous cases and those with >3 copies, LR-PCR and Sanger sequencing may still be necessary for determination of the duplicated allele.